Despite the selective apoptosis-inducing properties of TRAIL mediated by DR4/DR5 for cancer cells, clinical trials are constrained by several factors, including its short half-life, poor stability, and challenges in effective delivery to tumor sites [14,15]. Here, TNFRSF10A is linked to neoplasm.